Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer

14 Dec 2012

Abstract excerpt

BACKGROUND: Pancreatic cancer is a highly malignant disease with an extremely poor prognosis. Histone deacetylase inhibitors (HDACIs) have shown promising antitumor activities against preclinical models of pancreatic cancer, either alone or in combination with chemotherapeutic agents. In this study, we sought to identify clinically relevant histone deacetylases (HDACs) to guide the selection of HDAC inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23251689
DOI: 10.1371/journal.pone.0052095

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic CancerPMID 23251689Read ↗

Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.Semantic proximity Read ↗

Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer CellsSemantic proximity Read ↗

An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase InhibitorsSemantic proximity Read ↗

Histone Deacetylase Inhibitors Restore Cancer Cell Sensitivity towards T Lymphocytes Mediated Cytotoxicity in Pancreatic CancerSemantic proximity Read ↗

Role of histone deacetylases in pancreas: Implications for pathogenesis and therapySemantic proximity Read ↗

Epigenetic Targeting of Aberrant Transcriptional Modulation in Pancreatic CancerSemantic proximity Read ↗

HDAC Inhibition Sensitizes Pancreatic Tumors to DNA Damage by Global Redistribution of the Transcriptional MachinerySemantic proximity Read ↗

Targeting HDACs in Pancreatic Neuroendocrine Tumor ModelsSemantic proximity Read ↗

High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivoSemantic proximity Read ↗

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cellsSemantic proximity Read ↗

Epigenetic targeting in pancreatic cancerSemantic proximity Read ↗

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.